Oragenics Inc. reported on May 9, 2025, a net loss of $2.22 million for its first quarter ended March 31, 2025. This figure reflects the company's ongoing status as a development-stage biotechnology firm.
As of March 31, 2025, Oragenics held cash and cash equivalents of $3.42 million. This cash position provides an estimated runway through the third quarter of 2025, highlighting the critical need for additional financing.
The reported net loss and limited cash runway underscore the company's reliance on external funding to advance its clinical pipeline. Oragenics continues to seek capital to support its operations and planned clinical trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.